Angiotensin 1-7 vs Adrenomedullin

Angiotensin 1-7 and Adrenomedullin are both research peptides investigated across multiple preclinical and early clinical contexts. Angiotensin 1-7, a short heptapeptide, acts as a counter-regulatory component of the renin-angiotensin system, opposing angiotensin II-driven vasoconstriction and inflammation. Adrenomedullin, a larger 52-amino-acid peptide, functions as a potent vasodilator with natriuretic and cardioprotective properties, and its mid-regional fragment (MR-proADM) is studied as a prognostic biomarker in sepsis and heart failure. This comparison highlights their mechanistic divergence, evidence bases, and safety profiles to guide researchers in selecting the appropriate peptide for specific experimental models.

Angiotensin 1-7 is a heptapeptide (sequence: Asp-Arg-Val-Tyr-Ile-His-Pro, molecular weight ~899.0 g/mol) generated mainly through the enzymatic activity of ACE2 on angiotensin II. It primarily signals through the Mas receptor, initiating a cascade of effects that promote vasodilation, anti-fibrotic activity, and anti-inflammatory responses. Preclinical studies indicate that Angiotensin 1-7 confers cardioprotective benefits in models of heart failure, reduces fibrosis in both renal and cardiac tissues, and lowers blood pressure in hypertensive animal models. However, the evidence base remains in the early stages, with no FDA-approved therapeutic indications as of now. The peptide's extremely short plasma half-life—on the order of minutes—poses challenges for sustained therapeutic effects, necessitating continuous infusion or the development of modified formulations to enhance its efficacy in experimental settings.

Adrenomedullin is a 52-amino-acid peptide (molecular weight ~6028 g/mol) first identified in human pheochromocytoma. It is widely distributed in various tissues, including the cardiovascular system, lungs, kidneys, and adrenal glands, where it exerts its effects primarily via cAMP-dependent pathways and the release of nitric oxide. Research has demonstrated that the mid-regional fragment, MR-proADM, serves as a valuable prognostic biomarker in sepsis and acute heart failure, with studies indicating a strong correlation between MR-proADM levels and mortality risk. The full-length peptide has shown significant vasodilatory effects during human experimental infusions; however, its therapeutic application remains investigational. Notably, Adrenomedullin's larger molecular size and broader tissue distribution suggest distinct pharmacokinetic and pharmacodynamic properties compared to Angiotensin 1-7, including a longer half-life and the potential for reflex tachycardia.

While Angiotensin 1-7 and Adrenomedullin share cardiovascular effects, their research applications diverge significantly. Angiotensin 1-7 is predominantly explored within the context of the renin-angiotensin system, particularly in studies involving hypertension, cardiac fibrosis, and metabolic disorders. In contrast, Adrenomedullin research has centered around its role in sepsis prognostication through MR-proADM, the development of biomarkers for heart failure, and the mechanisms of vasodilation in conditions such as pulmonary hypertension. Both peptides are under investigation for their organ protective capabilities, but their functionalities cater to different aspects of cardiovascular pathology: Angiotensin 1-7 is more relevant to chronic conditions characterized by cardiovascular remodeling, whereas Adrenomedullin is pivotal in acute critical care settings and biomarker discovery.

In terms of safety, Angiotensin 1-7 lacks human safety data derived from controlled clinical trials. The anticipated pharmacological effect of this peptide is hypotension, which represents its primary risk factor. Given its extremely short plasma half-life, continuous infusion or specific formulation adjustments are required for any potential therapeutic applications, which may limit its practical use in research contexts. Similarly, Adrenomedullin has not been evaluated for safety in controlled therapeutic trials involving human subjects. Experimental intravenous infusions in healthy volunteers have reported instances of hypotension and reflex tachycardia, suggesting a theoretical risk of excessive vasodilation and hemodynamic instability. Consequently, both peptides necessitate careful monitoring and dose management in preclinical studies to mitigate the risk of adverse hemodynamic events.